一线医药

First-line Pharma is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule drugs for oncology. The company's primary focus is on the development of dual inhibitors targeting the IDO1 and TDO pathways to overcome immune suppression in the tumor microenvironment. Its lead candidate, FL-442, is a potent dual IDO1/TDO inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. By targeting these metabolic checkpoints, First-line Pharma aims to provide new therapeutic options for patients who are resistant to current immunotherapies.